AMARIN CORP PLC\UK Sales-type Lease, Interest Income
AMARIN CORP PLC\UK (AMRN) reported Sales-type Lease, Interest Income of $12.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Other Income
us-gaap:SalesTypeLeaseInterestIncome · last filed 2026-07-29
- AMARIN CORP PLC\UK sales-type lease, interest income for the quarter ending 2026-06-30 was $12.00K, a 14.29% decline year-over-year.
- AMARIN CORP PLC\UK sales-type lease, interest income for the quarter ending 2026-03-31 was $13.00K, a 13.33% decline year-over-year.
- AMARIN CORP PLC\UK sales-type lease, interest income for the quarter ending 2025-12-31 was $14.00K, a 6.67% decline year-over-year.
- AMARIN CORP PLC\UK sales-type lease, interest income for the quarter ending 2025-09-30 was $14.00K, a 6.67% decline year-over-year.
- AMARIN CORP PLC\UK sales-type lease, interest income for fiscal 2025 was $56.00K, a 9.68% decline from fiscal 2024.
- AMARIN CORP PLC\UK sales-type lease, interest income for fiscal 2024 was $62.00K, a 1.64% increase from fiscal 2023.
- AMARIN CORP PLC\UK sales-type lease, interest income for fiscal 2023 was $61.00K.
| Period end | Sales-type Lease, Interest Income 3 month | Sales-type Lease, Interest Income 6 month | Sales-type Lease, Interest Income 9 month | Sales-type Lease, Interest Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.00K 10-Q · filed 2026-07-29 | $25.00K 10-Q · filed 2026-07-29 | $39.00K derived: sum of 3 quarters · filed 2026-07-29 | $53.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $13.00K 10-Q · filed 2026-04-29 | $27.00K derived: sum of 2 quarters · filed 2026-04-29 | $41.00K derived: sum of 3 quarters · filed 2026-04-29 | $55.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $28.00K derived: sum of 2 quarters · filed 2026-03-02 | $42.00K derived: sum of 3 quarters · filed 2026-07-29 | $56.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $14.00K 10-Q · filed 2025-10-29 | $28.00K derived: sum of 2 quarters · filed 2026-07-29 | $42.00K 10-Q · filed 2025-10-29 | $58.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $14.00K 10-Q · filed 2026-07-29 | $29.00K 10-Q · filed 2026-07-29 | $44.00K derived: sum of 3 quarters · filed 2026-07-29 | $59.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $15.00K 10-Q · filed 2026-04-29 | $30.00K derived: sum of 2 quarters · filed 2026-04-29 | $45.00K derived: sum of 3 quarters · filed 2026-04-29 | $61.00K derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $30.00K derived: sum of 2 quarters · filed 2026-03-02 | $46.00K derived: sum of 3 quarters · filed 2026-03-02 | $62.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $15.00K 10-Q · filed 2025-10-29 | $31.00K derived: sum of 2 quarters · filed 2025-10-29 | $47.00K 10-Q · filed 2025-10-29 | $64.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $16.00K 10-Q · filed 2025-07-30 | $32.00K 10-Q · filed 2025-07-30 | $49.00K derived: sum of 3 quarters · filed 2026-03-02 | $66.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $16.00K 10-Q · filed 2025-05-07 | $33.00K derived: sum of 2 quarters · filed 2026-03-02 | $50.00K derived: sum of 3 quarters · filed 2026-03-02 | $67.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $34.00K derived: sum of 2 quarters · filed 2026-03-02 | $51.00K derived: sum of 3 quarters · filed 2026-03-02 | $61.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $17.00K 10-Q · filed 2024-10-30 | $34.00K derived: sum of 2 quarters · filed 2024-10-30 | $44.00K 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $17.00K 10-Q · filed 2024-07-31 | $28.00K 10-Q · filed 2024-07-31 | ||
| 2023-03-31 | $11.00K 10-Q · filed 2024-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |